PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism

NCT ID: NCT00166257

Last Updated: 2009-05-27

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 414 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-02-29
• Study Completion Date: 2011-05-31

Brief Summary

The purpose of this study is to compare two treatments strategies to prevent further attacks in patients who have suffered an stroke or occlusion of a major artery with no obvious reason other than a persistent small opening between the upper heart chambers

Detailed Description

In patients who have suffered a stroke or occlusion of a large artery in another body part of unknown origin a possible cause is a small opening between the upper heart chambers (patent foramen ovale, it is called). After birth this opening closes in 75% of the population, while it persists in 25% of people. It may allow a small blood clot to pass from the veins of the legs through the heart into the brain or other parts of the body. In order to reduce the risk for a further attack we have today more therapeutic options to choose from but it is unclear which strategy have the best outcome. This study is created to compare the effect of two treatment strategies:

1. Medical treatment The purpose of medical treatment is to dilute the blood to a degree, that no thrombus formation occurs. Since the opening in the heart persists, treatment is usually recommended lifelong. And patients treated with coumadin must undergo regular blood tests to ensure an adequate effect of the drug.

2. Catheter closure of patent foramen ovale An alternative method developed to close the small opening in the heart utilizes catheters which are introduced in a blood vessel in the groin and from there advanced to the heart. An umbrella device is then delivered through the catheter, positioned within the small defect and released. The umbrella is overgrown with own tissue within weeks to months and closes the small defect for ever.

Conditions

Embolism, Paradoxical; Heart Septal Defects, Atrial

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Medical antitrhombotic treatment

Group Type: ACTIVE_COMPARATOR

Medical antitrhombotic treatment

Intervention Type: DRUG

Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d

Device Implant

Percutaneous closure of patent foramen ovale

Group Type: EXPERIMENTAL

Percutaneous closure of patent foramen ovale

Intervention Type: DEVICE

Percutaneous implantation of an AMPLATZER® PFO Occluder

Interventions

Percutaneous closure of patent foramen ovale

Percutaneous implantation of an AMPLATZER® PFO Occluder

Intervention Type: DEVICE

Medical antitrhombotic treatment

Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age below 60 years
• Ischemic stroke or peripheral thromboembolism, radiologically verified
• Absence of an identifiable cause of embolism
• Echocardiographically verified patent foramen ovale
• Sufficient recovery from index event to allow independent daily activities

Exclusion Criteria

• Any identifiable cause for thromboembolic event other than PFO
• Cardiac diseases: mural thrombus, dilated cardiomyopathy, prosthetic heart valve or mitral stenosis, endocarditis, atrial fibrillation
• Vascular system: significant atherosclerosis or dissection of the aorta, collagen vascular disease, arteritis, vasculitis
• Pre-existing neurologic disorders or intracranial disease, e.g., multiple sclerosis, arteriovenous malformations, previous hemorrhage
• Contraindications for antithrombotic or anticoagulant therapy
• Patients already on chronic anticoagulant therapy for another disease
• Previous surgical or percutaneous PFO-closure
• Drug or alcohol abuse
• Pregnancy
• Septicemia or severe infectious disease
• Severe CNS disease
• No informed consent
• Foreseen difficulties with study compliance, especially the long-term follow-up

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott Medical Devices

INDUSTRY

Sponsor Role: collaborator

Foundation for Cardiovascular Research, Zurich

OTHER

Sponsor Role: lead

Responsible Party

University of Berne, Switzerland

Principal Investigators

Bernhard Meier, MD

Role: STUDY_CHAIR

Dept. Cardiology, University Hospital Insel, Berne, Switzerland

Locations

Monash Medical Centre

Melbourne, , Australia

Sir Charles Gairdner Hospital

Nedlands, , Australia

Alfred Hospital

Prahan, , Australia

Universitätsklinik für Innere Medizin II

Vienna, , Austria

A.Z. Sint-Jan AV

Bruges, , Belgium

University Hospital / Inselspital

Bern, , Switzerland

Countries

Australia; Austria; Belgium; Switzerland

References

Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Juni P; PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013 Mar 21;368(12):1083-91. doi: 10.1056/NEJMoa1211716.

Reference Type: DERIVED

PMID: 23514285 (View on PubMed)

Khattab AA, Windecker S, Juni P, Hildick-Smith D, Dudek D, Andersen HR, Ibrahim R, Schuler G, Walton AS, Wahl A, Mattle HP, Meier B. Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design. Trials. 2011 Feb 28;12:56. doi: 10.1186/1745-6215-12-56.

Reference Type: DERIVED

PMID: 21356042 (View on PubMed)

Other Identifiers

ICN98008

Identifier Type: -

Identifier Source: org_study_id